{"hands_on_practices": [{"introduction": "To truly understand the pathophysiology of cerebral venous thrombosis (CVT), we must begin with its fundamental effect on hemodynamics. The following problem invites you to apply Poiseuille's law, a core principle of fluid dynamics, to a simplified model of a dural venous sinus. This exercise is designed to provide a quantitative feel for the profound and non-linear relationship between vessel radius and blood flow, illustrating why even a non-occlusive thrombus can have severe consequences for cerebral venous drainage [@problem_id:4467838].", "problem": "A vascular neurology team is modeling the hemodynamic consequence of a nonocclusive thrombus in a dural venous sinus during cerebral venous thrombosis. Assume steady, laminar flow of an incompressible, Newtonian fluid through a rigid, cylindrical segment of sinus with fixed length $L$, dynamic viscosity $\\mu$ that remains constant, and a constant axial pressure gradient $\\Delta P / L$. The thrombus reduces the effective luminal radius from a baseline value $r_{0}$ to a new value $r_{1}$ such that $r_{1} = (1 - 0.20)\\, r_{0}$. Using Poiseuille’s law as the fundamental hemodynamic model, define the relative decrease in volumetric flow rate as $(Q_{0} - Q_{1})/Q_{0}$, where $Q_{0}$ is the baseline volumetric flow rate at radius $r_{0}$ and $Q_{1}$ is the post-thrombus volumetric flow rate at radius $r_{1}$. Compute the relative decrease in volumetric flow rate and express your final answer as a decimal or an exact fraction, without units. Do not round.", "solution": "The problem requires the computation of the relative decrease in volumetric flow rate in a cylindrical vessel after a reduction in its effective radius, under the assumption of steady, laminar flow of an incompressible, Newtonian fluid. The governing principle for this scenario is Poiseuille's law.\n\nFirst, we must validate the problem statement.\n\n**Step 1: Extract Givens**\n- **Flow conditions**: Steady, laminar flow.\n- **Fluid properties**: Incompressible, Newtonian fluid with constant dynamic viscosity $\\mu$.\n- **Vessel geometry**: Rigid, cylindrical segment of fixed length $L$.\n- **Driving force**: Constant axial pressure gradient $\\Delta P / L$.\n- **Baseline radius**: $r_{0}$.\n- **Post-thrombus radius**: $r_{1}$.\n- **Radius relationship**: $r_{1} = (1 - 0.20) r_{0}$.\n- **Governing model**: Poiseuille’s law.\n- **Baseline volumetric flow rate**: $Q_{0}$ (at radius $r_{0}$).\n- **Post-thrombus volumetric flow rate**: $Q_{1}$ (at radius $r_{1}$).\n- **Quantity to compute**: Relative decrease in volumetric flow rate, defined as $\\frac{Q_{0} - Q_{1}}{Q_{0}}$.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using the well-established Poiseuille's law to model fluid dynamics in a simplified, yet physically relevant, biological context. The assumptions (steady, laminar, incompressible, Newtonian flow in a rigid cylinder) are standard for first-order approximations in hemodynamics. The problem is well-posed, with all necessary information provided to calculate a unique, meaningful solution. The language is precise and objective. There are no scientific or logical contradictions, and the conditions are feasible within the context of a theoretical model. The problem is therefore deemed valid.\n\n**Step 3: Proceed to Solution**\n\nPoiseuille's law gives the volumetric flow rate $Q$ through a cylindrical pipe of radius $r$ and length $L$ as:\n$$Q = \\frac{\\pi \\Delta P r^{4}}{8 \\mu L}$$\nWe can rewrite this to explicitly show the dependence on the constant pressure gradient $\\frac{\\Delta P}{L}$:\n$$Q = \\frac{\\pi r^{4}}{8 \\mu} \\left(\\frac{\\Delta P}{L}\\right)$$\nThe baseline volumetric flow rate, $Q_{0}$, corresponding to the initial radius $r_{0}$, is:\n$$Q_{0} = \\frac{\\pi r_{0}^{4}}{8 \\mu} \\left(\\frac{\\Delta P}{L}\\right)$$\nThe post-thrombus volumetric flow rate, $Q_{1}$, corresponding to the reduced radius $r_{1}$, is:\n$$Q_{1} = \\frac{\\pi r_{1}^{4}}{8 \\mu} \\left(\\frac{\\Delta P}{L}\\right)$$\nThe problem asks for the relative decrease in volumetric flow rate, which is defined as $\\frac{Q_{0} - Q_{1}}{Q_{0}}$. We can simplify this expression:\n$$\\frac{Q_{0} - Q_{1}}{Q_{0}} = 1 - \\frac{Q_{1}}{Q_{0}}$$\nTo compute this, we first find the ratio $\\frac{Q_{1}}{Q_{0}}$ by substituting the expressions from Poiseuille's law:\n$$\\frac{Q_{1}}{Q_{0}} = \\frac{\\frac{\\pi r_{1}^{4}}{8 \\mu} \\left(\\frac{\\Delta P}{L}\\right)}{\\frac{\\pi r_{0}^{4}}{8 \\mu} \\left(\\frac{\\Delta P}{L}\\right)}$$\nThe terms $\\pi$, $8$, $\\mu$, and the constant pressure gradient $\\frac{\\Delta P}{L}$ are identical in the numerator and denominator, so they cancel out:\n$$\\frac{Q_{1}}{Q_{0}} = \\frac{r_{1}^{4}}{r_{0}^{4}} = \\left(\\frac{r_{1}}{r_{0}}\\right)^{4}$$\nThe problem provides the relationship between the radii: $r_{1} = (1 - 0.20) r_{0}$, which simplifies to $r_{1} = 0.80 r_{0}$. From this, we derive the ratio of the radii:\n$$\\frac{r_{1}}{r_{0}} = 0.80$$\nNow, substitute this value into the equation for the ratio of flow rates:\n$$\\frac{Q_{1}}{Q_{0}} = (0.80)^{4}$$\nCalculating the power:\n$$(0.80)^{2} = 0.64$$\n$$(0.80)^{4} = (0.64)^{2} = 0.4096$$\nSo, $\\frac{Q_{1}}{Q_{0}} = 0.4096$. This indicates that the flow rate is reduced to $40.96\\%$ of its original value.\n\nFinally, we compute the relative decrease in volumetric flow rate:\n$$\\frac{Q_{0} - Q_{1}}{Q_{0}} = 1 - \\frac{Q_{1}}{Q_{0}} = 1 - 0.4096 = 0.5904$$\nThis result signifies a $59.04\\%$ decrease in blood flow due to the $20\\%$ reduction in the sinus radius. The dependence of flow rate on the fourth power of the radius leads to this substantial hemodynamic consequence.", "answer": "$$\\boxed{0.5904}$$", "id": "4467838"}, {"introduction": "Building on the hemodynamic principles, the next step is translating this knowledge into clinical and diagnostic reasoning. Venous pathology creates injury patterns that are fundamentally different from those caused by arterial occlusion or hypertensive rupture because they are constrained by the anatomy of venous drainage territories. This practice problem challenges you to integrate imaging findings with pathophysiological logic to distinguish a CVT-related venous hemorrhagic infarct from its mimics, a crucial skill in neuroradiology and emergency neurology [@problem_id:4467864].", "problem": "A central principle of cerebral perfusion is that the volumetric flow $Q$ through capillaries is driven by the pressure gradient across the microvascular bed, $Q = (P_a - P_v)/R$, where $P_a$ is arterial pressure, $P_v$ is venous pressure, and $R$ is microvascular resistance. When venous outflow is obstructed, $P_v$ rises, the effective driving gradient $(P_a - P_v)$ falls, and capillary hydrostatic pressure increases locally, leading to blood–brain barrier failure, predominant vasogenic edema, and a propensity for hemorrhagic transformation within the draining venous territory. Conversely, chronic systemic hypertension elevates $P_a$ and predisposes deep perforator arterioles to structural failure and rupture (for example Charcot–Bouchard microaneurysm rupture), producing solitary, round to ovoid intraparenchymal hemorrhages in characteristic deep locations independent of cortical venous drainage patterns.\n\nA clinician must discriminate cerebral venous thrombosis–related venous hemorrhagic infarcts from hypertensive deep intraparenchymal hemorrhages using three axes: location, imaging morphology, and venous territory logic. Consider the following composite options, each blending these axes into a single claim. Select ALL options in which the triad is internally consistent and specifically favors a venous hemorrhagic infarct due to cerebral venous thrombosis rather than a hypertensive deep hemorrhage.\n\nA. Parasagittal cortical–subcortical multifocal hemorrhages with irregular gyriform edema that crosses arterial boundaries on non-contrast Computed Tomography (CT), accompanied by a hyperdense superior sagittal sinus; logic: thrombosis of the superior sagittal sinus elevates $P_v$, reduces $(P_a - P_v)$, and produces hemorrhagic infarction within its superficial cortical venous territory.\n\nB. Solitary, spherical hematoma centered in the putamen with smooth margins and prominent intraventricular extension on CT, with normal dural sinus density; logic: transverse sinus occlusion explains the deep perforator rupture and location.\n\nC. Bilateral thalamic hemorrhagic lesions with surrounding edema on Magnetic Resonance Imaging (MRI), with loss of normal flow voids of the internal cerebral veins and nonvisualization on Magnetic Resonance Venography; logic: deep venous system thrombosis of the internal cerebral veins and vein of Galen elevates $P_v$, compromises $Q$, and produces venous territory hemorrhagic infarction in the thalami.\n\nD. Single, ovoid pontine hemorrhage of homogeneous density on CT with deep gray matter–predominant microbleeds on Susceptibility Weighted Imaging (SWI), no cortical involvement, and normal dural sinuses; logic: superior sagittal sinus thrombosis accounts for the deep location and morphology.\n\nE. Multiple wedge-shaped hemorrhagic lesions confined to a single arterial territory with abrupt vessel cutoff on Computed Tomography Angiography (CTA) and normal venous sinuses; logic: venous congestion within the affected arterial bed explains the pattern.\n\nChoose all that apply.", "solution": "The user requires a critical validation of the problem statement, followed by a derivation of the solution based on the provided principles of cerebral hemodynamics.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\nThe problem statement provides the following principles and definitions:\n\n*   **Governing Principle:** Volumetric cerebral blood flow, $Q$, is defined by the equation $Q = (P_a - P_v)/R$, where $P_a$ is arterial pressure, $P_v$ is venous pressure, and $R$ is microvascular resistance.\n*   **Pathophysiology of Venous Outflow Obstruction (e.g., Cerebral Venous Thrombosis - CVT):**\n    *   Venous outflow is obstructed.\n    *   Venous pressure, $P_v$, rises.\n    *   The driving pressure gradient, $(P_a - P_v)$, falls.\n    *   Local capillary hydrostatic pressure increases.\n    *   Consequences include: blood–brain barrier failure, vasogenic edema (predominantly), and hemorrhagic transformation.\n    *   The injury pattern occurs within the specific draining venous territory.\n*   **Pathophysiology of Chronic Systemic Hypertension:**\n    *   Arterial pressure, $P_a$, is elevated.\n    *   This predisposes deep perforator arterioles (e.g., leading to Charcot–Bouchard microaneurysms) to rupture.\n    *   The result is a solitary, round to ovoid intraparenchymal hemorrhage.\n    *   Locations are characteristically deep (e.g., putamen, thalamus, pons).\n    *   The pattern is independent of cortical venous drainage patterns.\n*   **Discrimination Task:** Use three axes—location, imaging morphology, and venous territory logic—to distinguish CVT-related venous hemorrhagic infarcts from hypertensive deep intraparenchymal hemorrhages.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem statement is subjected to validation against the required criteria.\n\n*   **Scientifically Grounded:** The problem is founded on core principles of neurophysiology and cardiovascular fluid dynamics. The relationship $Q \\propto \\Delta P$ is a direct application of Ohm's law to hemodynamics, a standard and fundamental concept. The descriptions of the pathophysiology of cerebral venous thrombosis and hypertensive hemorrhage are accurate and consistent with established medical science in neurology and neuroradiology. The problem is free of pseudoscience or factual errors.\n*   **Well-Posed:** The problem is clearly structured. It provides two distinct pathophysiological models and asks the solver to identify which of the provided scenarios (options) are internally consistent with one model (venous thrombosis) and inconsistent with the other (hypertensive hemorrhage). The task is to evaluate the logical consistency of each option's \"triad\" (location, morphology, logic). A definite solution can be derived by applying the given principles.\n*   **Objective:** The language used is precise, technical, and objective, employing standard terminology from neuroradiology and neurology (e.g., \"parasagittal,\" \"gyriform edema,\" \"putamen,\" \"Magnetic Resonance Venography\"). There are no subjective or ambiguous statements that would preclude a rigorous analysis.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, and objective. The provided information is self-contained and sufficient to evaluate the options. Therefore, I will proceed to the solution.\n\n### Solution Derivation\n\nThe core task is to evaluate each option to determine if its combination of location, morphology, and explanatory logic is internally consistent and specific to a venous hemorrhagic infarct, as defined by the problem statement. A venous infarct is caused by elevated $P_v$, results in injury patterns conforming to venous drainage territories, and often has an irregular, edematous, and multifocal appearance. A hypertensive hemorrhage is caused by elevated $P_a$, results in a solitary, round/ovoid hemorrhage in deep brain locations, and is independent of venous territories.\n\n**Evaluation of Option A:**\n*   **Findings:** \"Parasagittal cortical–subcortical multifocal hemorrhages with irregular gyriform edema that crosses arterial boundaries on non-contrast Computed Tomography (CT), accompanied by a hyperdense superior sagittal sinus\".\n*   **Logic:** \"thrombosis of the superior sagittal sinus elevates $P_v$, reduces $(P_a - P_v)$, and produces hemorrhagic infarction within its superficial cortical venous territory.\"\n*   **Analysis:** The location (parasagittal) is the precise drainage territory of the superior sagittal sinus (SSS). The morphology (multifocal, irregular, crossing arterial boundaries, significant edema) is classic for venous infarction, which does not respect arterial territory maps. A hyperdense SSS on non-contrast CT (the \"dense triangle\" or \"cord\" sign) is a direct radiological sign of acute thrombosis. The logic provided correctly links the SSS thrombosis to an increase in $P_v$ within its territory, a decreased perfusion gradient $(P_a - P_v)$, and the resultant hemorrhagic infarction. The entire triad is self-consistent and pathognomonic for a venous infarct due to SSS thrombosis.\n*   **Verdict:** **Correct**.\n\n**Evaluation of Option B:**\n*   **Findings:** \"Solitary, spherical hematoma centered in the putamen with smooth margins and prominent intraventricular extension on CT, with normal dural sinus density\".\n*   **Logic:** \"transverse sinus occlusion explains the deep perforator rupture and location.\"\n*   **Analysis:** The findings describe the archetypal appearance of a hypertensive deep intraparenchymal hemorrhage. The location (putamen) is the most common site for such a hemorrhage. The morphology (solitary, spherical, smooth margins) is characteristic of an arterial rupture, not a venous infarct. \"Normal dural sinus density\" explicitly argues against a dural sinus thrombosis. The logic is flawed in two ways: $1$. Transverse sinus occlusion causes infarction in the temporal and occipital lobes, not the putamen. $2$. It incorrectly attributes a \"deep perforator rupture\" (an arterial event) to a venous occlusion. The findings are consistent with hypertensive hemorrhage, but the logic attempts to incorrectly attribute them to a venous cause. The triad is internally inconsistent.\n*   **Verdict:** **Incorrect**.\n\n**Evaluation of Option C:**\n*   **Findings:** \"Bilateral thalamic hemorrhagic lesions with surrounding edema on Magnetic Resonance Imaging (MRI), with loss of normal flow voids of the internal cerebral veins and nonvisualization on Magnetic Resonance Venography\".\n*   **Logic:** \"deep venous system thrombosis of the internal cerebral veins and vein of Galen elevates $P_v$, compromises $Q$, and produces venous territory hemorrhagic infarction in the thalami.\"\n*   **Analysis:** The internal cerebral veins drain the thalami and other deep gray matter structures. Because these veins are midline and drain bilaterally paired structures, thrombosis often leads to bilateral injury, especially in the thalami. This location is therefore highly suggestive of deep venous system thrombosis. The imaging findings (\"loss of normal flow voids,\" which indicates slow or absent flow, and nonvisualization on venography) are direct evidence of thrombosis in the specified veins. The logic correctly attributes the bilateral thalamic injury to an increase in local $P_v$ from the deep venous thrombosis, which is the exact pathophysiology of a venous infarct in this territory. The triad is self-consistent and classic for deep cerebral venous thrombosis.\n*   **Verdict:** **Correct**.\n\n**Evaluation of Option D:**\n*   **Findings:** \"Single, ovoid pontine hemorrhage of homogeneous density on CT with deep gray matter–predominant microbleeds on Susceptibility Weighted Imaging (SWI), no cortical involvement, and normal dural sinuses\".\n*   **Logic:** \"superior sagittal sinus thrombosis accounts for the deep location and morphology.\"\n*   **Analysis:** The findings describe a classic hypertensive brainstem hemorrhage. The pons is a common location, and the associated microbleeds seen on SWI are a strong indicator of chronic hypertensive microangiopathy. The logic is anatomically false. The superior sagittal sinus drains the cerebral convexity and has no drainage territory in the pons. Therefore, SSS thrombosis cannot cause a pontine hemorrhage. The findings point to hypertensive disease, while the logic invokes an anatomically impossible venous mechanism. The triad is internally inconsistent.\n*   **Verdict:** **Incorrect**.\n\n**Evaluation of Option E:**\n*   **Findings:** \"Multiple wedge-shaped hemorrhagic lesions confined to a single arterial territory with abrupt vessel cutoff on Computed Tomography Angiography (CTA) and normal venous sinuses\".\n*   **Logic:** \"venous congestion within the affected arterial bed explains the pattern.\"\n*   **Analysis:** The findings are the textbook description of an embolic arterial ischemic stroke with secondary hemorrhagic transformation. The key giveaways are the confinement to a \"single arterial territory\" and the \"abrupt vessel cutoff on CTA,\" which localizes the primary pathology to an artery. The logic is nonsensical; it attempts to explain a purely arterial pattern with a venous mechanism (\"venous congestion\"). An injury that respects arterial boundaries is, by definition, arterial in origin. The triad is internally inconsistent and describes an arterial, not venous, event.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{AC}$$", "id": "4467864"}, {"introduction": "After establishing a diagnosis, the clinician's focus shifts to management, particularly the duration of anticoagulation. This final exercise simulates a common and critical clinical decision, moving beyond diagnosis to evidence-based therapeutics. You will be asked to weigh the time-dependent risk of recurrent thrombosis against the ongoing risk of treatment-induced bleeding, using real-world epidemiological data to determine an optimal strategy for an individual patient. This problem hones the ability to perform a quantitative risk-benefit analysis, which is the cornerstone of modern, personalized medicine [@problem_id:4467847].", "problem": "A $32$-year-old right-handed woman with no prior venous thromboembolism, no hormonal therapy, no pregnancy, no cancer, and no family history of thrombosis presented with $10$ days of worsening headache and papilledema. Magnetic Resonance Venography (MRV) confirmed thrombosis of the superior sagittal sinus and right transverse sinus without infarction. She received therapeutic low-molecular-weight heparin followed by a Direct Oral Anticoagulant (DOAC) and clinically improved. At $3$ months, she is asymptomatic; follow-up imaging shows partial recanalization. Laboratory testing off anticoagulation demonstrated no severe thrombophilia (no antithrombin deficiency, no protein C or protein S deficiency, no antiphospholipid antibodies, no prothrombin G20210A), and her renal function and blood pressure are normal. She has no prior or active gastrointestinal lesions and no other major bleeding risk factors.\n\nYou are asked to determine an optimal anticoagulation duration after this first unprovoked cerebral venous thrombosis (CVT) in this low-bleeding-risk patient, using the following well-tested epidemiologic facts as the foundational base and definitions of absolute risk and time-at-risk:\n\n- Absolute risk is the probability of an event in a defined time interval; when a hazard is approximately constant over an interval, the expected number of events over that interval equals the hazard rate multiplied by time-at-risk.\n- Published cohorts of patients with CVT without severe thrombophilia report that, after discontinuation of anticoagulation, the hazard of recurrent CVT is approximately $1.5$ per $100$ patient-years during the first year and approximately $0.5$ per $100$ patient-years thereafter.\n- Major bleeding on a DOAC in low-bleeding-risk adults occurs at approximately $1.0$ per $100$ patient-years, with intracranial hemorrhage approximately $0.2$ per $100$ patient-years.\n- When therapeutic anticoagulation is continued, the risk of recurrent CVT during treatment is very low relative to the off-treatment risk; for the purpose of decision analysis over months, it can be approximated as near $0$.\n\nAssume that risks within subintervals are approximately constant and additive over time, and that the patient’s risk profile remains stable.\n\nWhich of the following anticoagulation strategies best balances prevention of recurrent CVT against bleeding risk for this patient?\n\nA. Stop anticoagulation at $3$ months\n\nB. Stop anticoagulation at $6$ months\n\nC. Stop anticoagulation at $12$ months\n\nD. Continue anticoagulation indefinitely (no planned stop)", "solution": "We are asked to select an anticoagulation duration that optimizes the trade-off between preventing recurrent cerebral venous thrombosis (CVT) and incurring major bleeding while on anticoagulation, given specified hazards. We proceed from first principles:\n\n- By definition, if the hazard (events per patient-time) over an interval is approximately constant, then the expected absolute risk over a time window equals the hazard multiplied by the duration of that window.\n- The patient’s on-treatment recurrence hazard is approximated as near $0$ over the months considered, so time spent on anticoagulation largely suppresses recurrent CVT risk. Conversely, time off anticoagulation accrues recurrent CVT risk at the off-treatment hazards described.\n- Major bleeding accrues only when the patient remains on anticoagulation, at approximately $1.0$ per $100$ patient-years.\n\nWe compare strategies by estimating the incremental absolute risk of recurrent CVT prevented by remaining on therapy versus the absolute risk of major bleeding incurred, focusing on two epochs: the first year (higher recurrent CVT hazard of approximately $1.5$ per $100$ patient-years) and the period after the first year (lower recurrent CVT hazard of approximately $0.5$ per $100$ patient-years).\n\nFirst, quantify hazards as absolute risks over months:\n\n- First-year off-treatment recurrent CVT hazard: $1.5$ per $100$ patient-years equals $0.015$ events per patient-year. Over $6$ months, the absolute risk is approximately $0.015 \\times 0.5 = 0.0075$ or $0.75\\%$. Over $9$ months, it is approximately $0.015 \\times 0.75 = 0.01125$ or $1.125\\%$.\n- Beyond $12$ months, off-treatment recurrent CVT hazard: $0.5$ per $100$ patient-years equals $0.005$ events per patient-year. Over $12$ months, the absolute risk is approximately $0.005 \\times 1 = 0.005$ or $0.5\\%$.\n- Major bleeding on DOAC: $1.0$ per $100$ patient-years equals $0.01$ events per patient-year. Over $6$ months, the absolute risk is approximately $0.01 \\times 0.5 = 0.005$ or $0.5\\%$. Over $9$ months, it is approximately $0.01 \\times 0.75 = 0.0075$ or $0.75\\%$. Over $12$ months, it is approximately $0.01 \\times 1 = 0.01$ or $1.0\\%$.\n\nNow evaluate each strategy. We take “additional time on anticoagulation” to prevent off-treatment recurrent CVT risk within the first year, when this risk is front-loaded, while incurring bleeding risk while on treatment. Because monthly on-treatment recurrence is near $0$, the benefit of any extension is roughly equal to the off-treatment hazard during that time window.\n\nOption A: Stop at $3$ months.\n- Compared with stopping at $12$ months, stopping at $3$ months would forgo $9$ additional months of first-year protection. The off-treatment first-year hazard is approximately $1.5$ per $100$ patient-years, or $0.015$ per patient-year. Over $9$ months, expected recurrent CVT prevented by continuing would be approximately $0.01125$ ($1.125\\%$).\n- The cost (major bleeding) of continuing for those $9$ months is approximately $0.0075$ ($0.75\\%$).\n- Net clinical balance in absolute events favored by continuing to $12$ months versus stopping at $3$ months is approximately $1.125\\% - 0.75\\% = 0.375\\%$ fewer severe thrombotic events, with the additional consideration that recurrent CVT carries high morbidity and that on-treatment intracranial hemorrhage risk is low (approximately $0.2$ per $100$ patient-years, or $0.15\\%$ over $9$ months). Therefore, stopping at $3$ months is suboptimal in this unprovoked case and low bleeding risk profile. Verdict: Incorrect.\n\nOption B: Stop at $6$ months.\n- Compared with stopping at $12$ months, stopping at $6$ months forgoes $6$ months of first-year protection. Expected recurrent CVT prevented by continuing through months $6$ to $12$ is approximately $0.0075$ ($0.75\\%$), as computed above for a $6$-month window in the first year.\n- The bleeding cost of those extra $6$ months is approximately $0.5\\%$.\n- Net difference is approximately $0.75\\% - 0.5\\% = 0.25\\%$ in favor of continuing, again with the clinical reality that recurrent CVT has substantial neurological morbidity and mortality while on-DOAC intracranial hemorrhage risk is low (approximately $0.1\\%$ over $6$ months).\n- Thus, in a low-bleeding-risk patient, $12$ months provides a better trade-off than $6$ months. Verdict: Incorrect.\n\nOption C: Stop at $12$ months.\n- This captures the entire first year, during which recurrent CVT risk off treatment is higher (approximately $1.5$ per $100$ patient-years). Continuing beyond $12$ months would then target a lower off-treatment hazard of approximately $0.5$ per $100$ patient-years ($0.5\\%$ per year), while incurring a higher major bleeding hazard of approximately $1.0\\%$ per year on a DOAC.\n- Over each additional year beyond $12$ months, the expected recurrent CVT prevented is approximately $0.5\\%$, while the expected major bleeding risk incurred is approximately $1.0\\%$ (with approximately $0.2\\%$ intracranial hemorrhage). This indicates diminishing and likely unfavorable net returns to continuing anticoagulation indefinitely for this low-risk profile in the absence of severe thrombophilia or recurrent events.\n- Therefore, completing $12$ months and stopping is consistent with optimizing the early, higher-risk period while avoiding net harm thereafter. Verdict: Correct.\n\nOption D: Continue indefinitely (no planned stop).\n- Indefinite anticoagulation yields ongoing protection, but the off-treatment recurrent CVT hazard beyond $12$ months is approximately $0.5\\%$ per year, whereas the on-treatment major bleeding hazard is approximately $1.0\\%$ per year (with intracranial hemorrhage approximately $0.2\\%$ per year). Thus, on a per-year basis beyond $12$ months, expected harms from bleeding exceed expected prevention of recurrent CVT in this risk profile.\n- Indefinite anticoagulation may be appropriate in settings of severe thrombophilia or prior recurrent venous thrombosis, but those features are absent here. Verdict: Incorrect.\n\nSynthesis from first principles:\n- Using the definition of absolute risk over time and the empirically observed hazard structure (higher in year $1$, lower thereafter), the expected benefit of anticoagulation is largest while traversing the first year. Over months $6$ to $12$, the additional absolute prevention of recurrent CVT (approximately $0.75\\%$) still exceeds the bleeding risk (approximately $0.5\\%$), favoring completion of $12$ months.\n- After $12$ months, the off-treatment recurrent CVT hazard (approximately $0.5\\%$ per year) is lower than the on-treatment major bleeding risk (approximately $1.0\\%$ per year), so continued therapy has unfavorable expected value in this low-bleeding-risk, low-recurrence-risk scenario.\n- Therefore, stopping anticoagulation at $12$ months best aligns with the recurrence data and risk trade-offs presented.", "answer": "$$\\boxed{C}$$", "id": "4467847"}]}